Omalizumab-igec

Omalizumab is a prescription biologic medication known as a monoclonal antibody that targets immunoglobulin E, which is an antibody in the immune system that triggers allergic reactions. It is primarily used to treat patients with moderate to severe persistent asthma caused by year-round allergens when their symptoms are not properly managed with traditional inhaled corticosteroids. Beyond respiratory issues, it is also prescribed for adults to treat chronic rhinosinusitis with nasal polyps, helping to reduce the size of the polyps and improve symptoms like nasal congestion. This medication is also frequently used for the treatment of chronic spontaneous urticaria, a condition characterized by chronic hives that do not have an identifiable cause and fail to respond to standard antihistamine therapy. Furthermore, it has been approved for reducing the risk of severe allergic reactions, including anaphylaxis, in individuals with food allergies who may be accidentally exposed to certain allergens. The medication is typically administered through a subcutaneous injection every two or four weeks, depending on the specific condition and the patient's weight and initial immunoglobulin levels.